Paradoxical effects on force generation after efficient β1-adrenoceptor knockdown in reconstituted heart tissue

Journal of Pharmacology and Experimental Therapeutics

Volumn 349, Issue 4, 2014, Pages 39-46

  Neuber, Christiane ^a,b   Müller, Oliver J ^b,c   Hansen, Felix C ^a,b   Eder, Alexandra ^a,b   Witten, Anika ^d   Rühle, Frank ^d   Stoll, Monika ^d   Katus, Hugo A ^b,c   Eschenhagen, Thomas ^a,b   El Armouche, Ali ^b,e,f  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRIDAE; ADRENERGIC BETA-1 RECEPTOR AGONISTS; ANIMALS; ANIMALS, NEWBORN; FEMALE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GENETIC VECTORS; ISOPROTERENOL; MALE; MICROARRAY ANALYSIS; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; RATS; RATS, INBRED LEW; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA-1; RNA, SMALL INTERFERING; TISSUE CULTURE TECHNIQUES; TISSUE ENGINEERING;

EID: 84896472945     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.210898     Document Type: Article

References (42)

1. Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, and Mukherjee SK (2003) RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev 67:657-685.
2. Bers DM (2002) Cardiac excitation-contraction coupling. Nature 415:198-205.
3. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, Baskerville S, Maksimova E, Robinson K, and Karpilow J, et al. (2006) 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 3:199-204.
4. Brodde OE, Bruck H, Leineweber K, and Seyfarth T (2001) Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. Basic Res Cardiol 96:528-538.
5. Brown L, Deighton NM, Bals S, Söhlmann W, Zerkowski HR, Michel MC, and Brodde OE (1992) Spare receptors for beta-adrenoceptor-mediated positive inotropic effects of catecholamines in the human heart. J Cardiovasc Pharmacol 19:222-232.
6. Brummelkamp TR, Bernards R, and Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550-553.
7. Cattin ME, Bertrand AT, Schlossarek S, Le Bihan MC, Skov Jensen S, Neuber C, Crocini C, Maron S, Lainé J, and Mougenot N, et al. (2013) Heterozygous Lmna-delK32 mice develop dilated cardiomyopathy through a combined pathomechanism of haploinsufficiency and peptide toxicity. Hum Mol Genet 22:3152-3164.
8. D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, Liggett SB, and Dorn GW, 2nd (1997) Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci USA 94:8121-8126.
9. El-Armouche A and Eschenhagen T (2009) Beta-adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev 14:225-241.
10. El-Armouche A, Rau T, Zolk O, Ditz D, Pamminger T, Zimmermann WH, Jäckel E, Harding SE, Boknik P, and Neumann J, et al. (2003) Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes. FASEB J 17:437-439.
11. El-Armouche A, Singh J, Naito H, Wittköpper K, Didié M, Laatsch A, Zimmermann WH, and Eschenhagen T (2007) Adenovirus-delivered short hairpin RNA targeting PKCalpha improves contractile function in reconstituted heart tissue. J Mol Cell Cardiol 43:371-376.
12. El-Armouche A, Wittköpper K, Degenhardt F, Weinberger F, Didié M, Melnychenko I, Grimm M, Peeck M, Zimmermann WH, and Unsöld B, et al. (2008) Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy. Cardiovasc Res 80:396-406.
13. Engelhardt S, Hein L, Wiesmann F, and Lohse MJ (1999) Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96:7059-7064.
14. Hansen A, Eder A, Bönstrup M, Flato M, Mewe M, Schaaf S, Aksehirlioglu B, Schwoerer AP, Uebeler J, and Eschenhagen T (2010) Development of a drug screening platform based on engineered heart tissue. Circ Res 107:35-44.
15. Hao J, Michalek C, Zhang W, Zhu M, Xu X, and Mende U (2006) Regulation of cardiomyocyte signaling by RGS proteins: differential selectivity towards G proteins and susceptibility to regulation. J Mol Cell Cardiol 41:51-61.
16. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, and Klotz KN (2004) Comparative pharmacology of human beta-adrenergic receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 369:151-159.
17. Huang Y, Wright CD, Merkwan CL, Baye NL, Liang Q, Simpson PC, and O'Connell TD (2007) An alpha1A-adrenergic-extracellular signal-regulated kinase survival signaling pathway in cardiac myocytes. Circulation 115:763-772.
18. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, and Linsley PS (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21:635-637.
19. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, Johnson JM, Lim L, Karpilow J, and Nichols K, et al. (2006) Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12:1197-1205.
20. Jensen BC, O'Connell TD, and Simpson PC (2011) Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure. J Mol Cell Cardiol 51:518-528.
21. Joseph SS, Lynham JA, Colledge WH, and Kaumann AJ (2004) Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol 369:525-532.
22. Kiriazis H, Wang K, Xu Q, Gao XM, Ming Z, Su Y, Moore XL, Lambert G, Gibbs ME, and Dart AM, et al. (2008) Knockout of beta(1)- and beta(2)-adrenoceptors attenuates pressure overload-induced cardiac hypertrophy and fibrosis. Br J Pharmacol 153:684-692.
23. Lee S, Schwinger RH, and Brixius K (2008) Genetically changed mice with chronic deficiency or overexpression of the beta-adrenoceptors - what can we learn for the therapy of heart failure? Pflugers Arch 455:767-774.
24. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, and Robertson AD, et al. (2002) Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346:1357-1365.
25. Luchtefeld M, Preuss C, Rühle F, Bogalle EP, Sietmann A, Figura S, Müller W, Grote K, Schieffer B, and Stoll M (2011) Gp130-dependent release of acute phase proteins is linked to the activation of innate immune signaling pathways. PLoS ONE 6: e19427.
26. Moran CM, Thomson AJ, Rog-Zielinska E, and Gray GA (2013) High-resolution echocardiography in the assessment of cardiac physiology and disease in preclinical models. Exp Physiol 98:629-644.
27. Qiu S, Adema CM, and Lane T (2005) A computational study of off-target effects of RNA interference. Nucleic Acids Res 33:1834-1847.
28. Raake PW, Schlegel P, Ksienzyk J, Reinkober J, Barthelmes J, Schinkel S, Pleger S, Mier W, Haberkorn U, Koch WJ et al. (2013) AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 34:1437-1347.
29. Ram R, Mickelsen DM, Theodoropoulos C, and Blaxall BC (2011) New approaches in small animal echocardiography: imaging the sounds of silence. Am J Physiol Heart Circ Physiol 301:H1765-H1780.
30. Rapacciuolo A, Esposito G, Caron K, Mao L, Thomas SA, and Rockman HA (2001) Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. J Am Coll Cardiol 38:876-882.
31. Rapundalo ST (1998) Cardiac protein phosphorylation: functional and pathophysiological correlates. Cardiovasc Res 38:559-588.
32. Rockman HA, Koch WJ, and Lefkowitz RJ (2002) Seven-transmembrane-spanning receptors and heart function. Nature 415:206-212.
33. Rohrer DK, Desai KH, Jasper JR, Stevens ME, Regula DP, Jr, Barsh GS, Bernstein D, and Kobilka BK (1996) Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects. Proc Natl Acad Sci USA 93: 7375-7380.
34. Rohrer DK, Schauble EH, Desai KH, Kobilka BK, and Bernstein D (1998) Alterations in dynamic heart rate control in the beta 1-adrenergic receptor knockout mouse. Am J Physiol 274:H1184-H1193.
35. Rohrer DK, Chruscinski A, Schauble EH, Bernstein D, and Kobilka BK (1999) Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors. J Biol Chem 274:16701-16708.
36. Saxena S, Jónsson ZO, and Dutta A (2003) Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem 278:44312-44319.
37. Schaaf S, Shibamiya A, Mewe M, Eder A, Stöhr A, Hirt MN, Rau T, Zimmermann W-H, Conradi L, and Eschenhagen T, et al. (2011) Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS ONE 6:e26397.
38. Schubert S, Grunert HP, Zeichhardt H, Werk D, Erdmann VA, and Kurreck J (2005) Maintaining inhibition: siRNA double expression vectors against coxsackieviral RNAs. J Mol Biol 346:457-465.
39. Stöhr A, Friedrich FW, Flenner F, Geertz B, Eder A, Schaaf S, Hirt MN, Uebeler J, Schlossarek S, Carrier L et al. (2013) Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice. J Mol Cell Cardiol 63:189-198.
40. Tsang S, Woo AY, Zhu W, and Xiao RP (2010) Deregulation of RGS2 in cardiovascular diseases. Front Biosci (Schol Ed.) 2:547-557.
41. Wettschureck N, Rütten H, Zywietz A, Gehring D, Wilkie TM, Chen J, Chien KR, and Offermanns S (2001) Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med 7:1236-1240.
42. Xiang Y and Kobilka BK (2003) Myocyte adrenoceptor signaling pathways. Science 300:1530-1532.